Zoetis (NYSE:ZTS) Releases Earnings Results, Beats Estimates By $0.03 EPS

Zoetis (NYSE:ZTS) posted its quarterly earnings data on Thursday. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03, Zacks reports. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis updated its FY 2025 guidance to 6.000-6.100 EPS.

Zoetis Stock Down 4.5 %

Shares of NYSE ZTS traded down $7.40 during mid-day trading on Friday, reaching $157.54. 7,656,606 shares of the company were exchanged, compared to its average volume of 2,578,743. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock has a market cap of $71.08 billion, a price-to-earnings ratio of 29.61, a P/E/G ratio of 2.77 and a beta of 0.90. Zoetis has a 1 year low of $144.80 and a 1 year high of $200.53. The firm has a 50-day moving average of $168.51 and a 200 day moving average of $178.81.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of research firms recently issued reports on ZTS. Morgan Stanley dropped their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Barclays boosted their price objective on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday. Finally, Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $214.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.